Sylvant

Chemical Namesiltuximab
Dosage FormInjection (intravenous; 100 mg, 400 mg)
Drug ClassReceptor antagonists
SystemBlood
CompanyEUSA Pharma
Approval Year2014

Indication

  • For the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
Last updated on 7/18/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Sylvant (siltuximab) Prescribing Information.2019EUSA Pharma (UK) Ltd., Breakspear Park, Hertfordshire